Comparative Pharmacology
Head-to-head clinical analysis: BUSULFAN versus MELPHALAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFAN versus MELPHALAN HYDROCHLORIDE.
BUSULFAN vs MELPHALAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that crosslinks DNA, primarily at guanine N7 positions, leading to DNA strand breaks and inhibition of DNA replication and transcription. It is cell cycle phase-nonspecific.
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
1-4 mg/day orally for remission induction in CML; 0.8-1 mg/kg every 6 hours orally for 4 days as part of myeloablative conditioning with cyclophosphamide.
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
None Documented
None Documented
Clinical Note
moderateBusulfan + Digoxin
"Busulfan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBusulfan + Digitoxin
"Busulfan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBusulfan + Deslanoside
"Busulfan may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBusulfan + Acetyldigitoxin
"Busulfan may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 2.5 to 4 hours (mean ~2.6 hours) after oral administration; prolonged to 3-5 hours with high-dose regimens. Half-life may increase with hepatic impairment.
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
Renal (10-50% unchanged), hepatic metabolism (primarily via glutathione S-transferases) with metabolites excreted in bile and urine. Fecal excretion minimal (<5%).
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Category C
Category D/X
Alkylating Agent
Alkylating Agent